TLPH TALPHERA, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1427925 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY-96.3%
TTM net income YoY-33.4%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-1,474,700.0%
Net margin-1,507,600.0%
FCF margin—
EBITDA margin—
Returns
ROE-143.4%
ROA-69.6%
ROIC (approx.)-172.6%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets46.3%
Debt / equity0.00x
Current ratio4.29x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.81x
Accruals ratio-13.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | $0 | $0 | $1,000 | $0 | $27,000 | $0 |
| R&D expense | $2.19M | $1.69M | $1.65M | $1.56M | $1.80M | $1.50M | $1.17M | $1.32M |
| SG&A expense | $1.95M | $2.23M | $2.30M | $1.89M | $1.62M | $2.19M | $1.77M | $1.67M |
| Operating income | -$4.14M | -$3.92M | -$3.95M | -$3.45M | -$3.42M | -$3.69M | -$2.92M | -$3.00M |
| Interest expense | — | — | — | — | — | — | — | $0 |
| Income tax | — | — | — | — | — | — | — | $0 |
| Net income | -$4.02M | -$4.31M | -$2.56M | -$3.77M | -$4.44M | -$3.49M | -$2.59M | -$1.87M |
| EBITDA | — | — | — | — | — | — | — | -$3.00M |
| EPS (basic) | -0.05 | -0.06 | -0.04 | — | -0.11 | -0.10 | -0.10 | — |
| EPS (diluted) | — | — | — | — | — | — | -0.10 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $10.66M | $742,000 | $3.82M | $5.89M | $3.46M | $6.79M | $5.39M | $8.86M |
| Short-term investments | $3.50M | $16.33M | $17.29M | $14.49M | $17.83M | — | — | $0 |
| Current assets | $14.76M | $17.99M | $21.34M | $20.90M | $21.92M | $7.70M | $6.18M | $9.42M |
| Intangibles | $8.82M | $8.82M | $8.82M | $8.82M | $8.82M | $8.82M | $8.82M | $8.82M |
| Total assets | $23.57M | $26.81M | $30.16M | $29.72M | $30.74M | $16.52M | $14.99M | $18.24M |
| Current liabilities | $4.63M | $4.19M | $4.03M | $3.81M | $3.21M | $2.63M | $1.99M | $2.65M |
| Total liabilities | $12.86M | $12.40M | $11.68M | $12.68M | $11.56M | $9.89M | $9.40M | $10.23M |
| Shareholders' equity | $10.71M | $14.41M | $18.48M | $17.04M | $19.18M | $6.63M | $5.60M | $8.00M |
| Shares outstanding | 51.95M | 51.91M | 50.05M | 49.33M | 45.59M | 20.52M | 17.10M | 17.03M |
| Cash flow statement | ||||||||
| Operating cash flow | -$3.03M | -$3.92M | -$3.40M | -$2.44M | -$2.51M | -$2.95M | -$3.47M | -$2.25M |
| Capital expenditure | — | — | — | — | — | — | — | $0 |
| Free cash flow | — | — | — | — | — | — | — | -$2.25M |
| Investing cash flow | $12.92M | $1.10M | -$2.71M | $3.47M | -$17.82M | $0 | $0 | $0 |
| Financing cash flow | $32,000 | -$261,000 | $4.04M | $1.40M | $16.99M | $4.35M | -$5,000 | $0 |
| Depreciation & amortization | — | — | — | — | — | — | — | $0 |
| Stock-based compensation | $292,000 | $243,000 | $214,000 | $185,000 | $152,000 | $166,000 | $196,000 | $230,000 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.